FINHUB Insights

ZTS · Q3 FY25 · Jul 1 – Sep 30, 2025

Zoetis Q3 FY25: where the revenue came from and where it went

Zoetis Q3 FY25: revenue $2.4B (+1% year over year). Net profit $0.7B. Largest cohort Parasiticides $0.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 4, 2025 10-Q
Sankey diagram of Zoetis's income statement for Q3 FY25: revenue of $2.4 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$2.4B +1% year over year
Gross profit$1.7B 72% margin
Operating profit$0.9B 36% margin
Net profit$0.7B 30% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 2.4 100% +1%
Parasiticides 0.6 25% +6%
Vaccines 0.5 21% +6%
Dermatology 0.5 21%
Other 0.2 8%
Pain Sedation 0.2 8% −7%
Other Pharmaceuticals 0.2 8% +5%
Swine 0.1 4% −15%
Animal Health Diagnostics 0.1 4% +9%
Cost of revenue−0.729%
Gross profit1.772% margin+1pp
SG&A−0.624%+0pp
Other−0.311%+0pp
Operating profit0.936% margin+0pp
Tax−0.2
Net profit0.730%+1pp
Filing on EDGAR More quarters of ZTS

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters